opacin and opacin-neo: neoadjuvant immunotherapy for advanced melanoma
Published 1 year ago • 68 plays • Length 1:39Download video MP4
Download video MP3
Similar videos
-
1:54
opacin-neo and prado: personalized neoadjuvant io for melanoma based on pathologic response
-
2:52
opacin-neo trial rfs and biomarker analyses: optimal neoadjuvant ipi/nivo dosing in melanoma
-
2:33
opacin-neo & prado 3-year results in stage iii melanoma: personalized neoadjuvant io benefits
-
1:16
neoadjuvant ipi nivo in stage iii melanoma: updates from opacin & opacin-neo
-
0:35
potential advantages of neoadjuvant immunotherapy for melanoma
-
1:30
omission of adjuvant therapy and tlnd in melanoma: insights from opacin-neo, prado, and nadina
-
2:53
opacin-neo: tmb and ifn-γ identified as biomarkers of pathologic response in melanoma
-
3:09
advances in utilizing neoadjuvant immunotherapy in melanoma
-
1:22
the personalization of neoadjuvant immunotherapy in stage iii melanoma
-
1:12
investigators present updated results of the opacin trial for melanoma
-
0:57
circulating immune cell subsets in patients with melanoma from the opacin-neo trial
-
1:48
dr. blank on the opacin, opacin-neo trials in stage iii macroscopic melanoma
-
2:43
clinical & tumor characteristics of patients with recurrent melanoma upon immunotherapy
-
2:12
omitting total lymph node dissection and adjuvant therapy in melanoma
-
1:20
neopele: neoadjuvant pembrolizumab and lenvatinib in resectable stage iii melanoma
-
2:10
neoadjuvant therapy for melanoma
-
5:18
neoadjuvant ipilimumab and nivolumab immunotherapy for resectable stage iii melanoma
-
1:14
adjuvant and neoadjuvant clinical trials for melanoma
-
1:09
clinical implications of neoadjuvant immunotherapy in cscc